Back to search

Netherlands· NL-f24c330bba05

Teysuno 15 mg/4,35 mg/11,8 mg harde capsules

A tegafur, kombinationen product containing gimeracil + oteracil kalium 0-water + tegafur, registered in Netherlands by Nordic Group BV. The same ATC class is registered in 9 of our 19 countries.

ATC L01BC53

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedTeysuno 15 mg/4,35 mg/11,8 mg harde c…ATCL01BC53REGISTER NO.NL-f24c330bba05PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Tegafur, kombinationen is registered in 9 of 19 countries.

Countries holding a registration under ATC L01BC53 (tegafur, kombinationen), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose

Tegafur, kombinationen · ATC L01BC53

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
GIMERACIL + OTERACIL KALIUM 0-WATER + TEGAFUR
Manufacturer
Nordic Group BV
Country
Netherlands (NL)
ATC code
L01BC53
ATC class
Tegafur, Kombinationen
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/11/669

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tegafur, kombinationen in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tegafur, kombinationen products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Teysuno
  • Iceland · Teysuno
  • Liechtenstein · Teysuno
  • Norway · Teysuno

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dbf39e6e-4b94-4c87-9939-cfe9700bf6f1
GET /v1/drugs/dbf39e6e-4b94-4c87-9939-cfe9700bf6f1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/teysuno-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Tegafur, Combinations",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp106311",
  "excipients": [
    "CARNAUBAWAS (E 903)",
    "GELATINE (E 441)",
    "GLYCERYLMONO-OLEAAT",
    "GRIJZE INKT",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT",
    "SCHELLAK (E 904)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "GIMERACIL",
    "OTERACIL KALIUM 0-WATER",
    "TEGAFUR"
  ],
  "leaflet_url": null,
  "authorised_at": "2011/03/14",
  "procedure_number": "EMEA/H/C/001242",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/11/669",
  "additional_monitoring": "N"
}

See everything about tegafur, kombinationen.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.